Enzo Biochem (ENZ) Competitors $0.99 -0.02 (-1.99%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ENZ vs. SERA, BDSX, EUDA, QIPT, PIII, XGN, BNR, MRAI, CCM, and OPGNShould you be buying Enzo Biochem stock or one of its competitors? The main competitors of Enzo Biochem include Sera Prognostics (SERA), Biodesix (BDSX), EUDA Health (EUDA), Quipt Home Medical (QIPT), P3 Health Partners (PIII), Exagen (XGN), Burning Rock Biotech (BNR), Marpai (MRAI), Concord Medical Services (CCM), and OpGen (OPGN). These companies are all part of the "healthcare" industry. Enzo Biochem vs. Sera Prognostics Biodesix EUDA Health Quipt Home Medical P3 Health Partners Exagen Burning Rock Biotech Marpai Concord Medical Services OpGen Enzo Biochem (NYSE:ENZ) and Sera Prognostics (NASDAQ:SERA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, community ranking, institutional ownership, profitability, dividends and analyst recommendations. Is ENZ or SERA more profitable? Sera Prognostics has a net margin of 0.00% compared to Enzo Biochem's net margin of -81.73%. Enzo Biochem's return on equity of -11.84% beat Sera Prognostics' return on equity.Company Net Margins Return on Equity Return on Assets Enzo Biochem-81.73% -11.84% -8.31% Sera Prognostics N/A -51.73%-36.94% Does the MarketBeat Community favor ENZ or SERA? Enzo Biochem received 202 more outperform votes than Sera Prognostics when rated by MarketBeat users. Likewise, 55.35% of users gave Enzo Biochem an outperform vote while only 38.46% of users gave Sera Prognostics an outperform vote. CompanyUnderperformOutperformEnzo BiochemOutperform Votes21255.35% Underperform Votes17144.65% Sera PrognosticsOutperform Votes1038.46% Underperform Votes1661.54% Which has higher earnings and valuation, ENZ or SERA? Enzo Biochem has higher revenue and earnings than Sera Prognostics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnzo Biochem$31.91M1.62-$26.08MN/AN/ASera Prognostics$310K656.88-$36.24M-$0.99-6.09 Does the media refer more to ENZ or SERA? In the previous week, Enzo Biochem and Enzo Biochem both had 1 articles in the media. Sera Prognostics' average media sentiment score of 0.91 beat Enzo Biochem's score of 0.00 indicating that Sera Prognostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enzo Biochem 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sera Prognostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in ENZ or SERA? 36.9% of Enzo Biochem shares are held by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are held by institutional investors. 15.5% of Enzo Biochem shares are held by insiders. Comparatively, 15.8% of Sera Prognostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, ENZ or SERA? Enzo Biochem has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Do analysts recommend ENZ or SERA? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enzo Biochem 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Sera Prognostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummarySera Prognostics beats Enzo Biochem on 8 of the 14 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Enzo Biochem News Delivered to You Automatically Sign up to receive the latest news and ratings for ENZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENZ vs. The Competition Export to ExcelMetricEnzo BiochemMedical laboratories IndustryMedical SectorNYSE ExchangeMarket Cap$52.77M$3.05B$5.05B$19.84BDividend Yield39.22%11.09%4.97%3.50%P/E RatioN/A11.1797.3437.73Price / Sales1.62208.381,218.4218.01Price / CashN/A376.8533.5117.90Price / Book0.914.905.804.86Net Income-$26.08M-$32.86M$119.07M$985.93M7 Day Performance-13.79%0.56%-1.83%0.45%1 Month Performance-13.41%-0.22%-3.64%1.05%1 Year Performance-21.66%26.01%31.62%24.67% Enzo Biochem Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENZEnzo Biochem0.5149 of 5 stars$0.99-2.0%N/A-22.3%$52.77M$31.91M0.00520SERASera Prognostics1.0479 of 5 stars$6.03-2.4%N/A+235.0%$208.71M$310,000.000.00120BDSXBiodesix2.6834 of 5 stars$1.19-4.0%$3.06+157.1%-16.2%$173.11M$65.56M-3.05220Negative NewsHigh Trading VolumeEUDAEUDA Health0.1736 of 5 stars$4.38+0.9%N/A+284.2%$106.88M$3.71M0.002QIPTQuipt Home Medical3.2122 of 5 stars$2.42-1.2%$6.25+158.3%-51.2%$105.57M$221.74M0.001,200News CoveragePIIIP3 Health Partners3.2506 of 5 stars$0.20-4.7%$2.38+1,065.4%-82.9%$75.44M$1.27B0.00500Analyst ForecastAnalyst RevisionHigh Trading VolumeXGNExagen4.7894 of 5 stars$4.20+19.0%$7.00+66.7%+169.2%$62.26M$52.55M0.00220Analyst RevisionGap UpHigh Trading VolumeBNRBurning Rock BiotechN/A$4.64+0.9%N/A-48.5%$47.51M$75.70M-0.971,390MRAIMarpai1.994 of 5 stars$1.64+13.1%$6.00+265.9%+80.2%$19.92M$37.15M0.00150CCMConcord Medical Services0.3558 of 5 stars$4.35-3.3%N/A-58.6%$18.88M$75.69M0.00970Gap UpOPGNOpGenN/A$1.99+1.5%N/A-55.8%$16.40M$3.42M0.00100News Coverage Related Companies and Tools Related Companies Sera Prognostics Competitors Biodesix Competitors EUDA Health Competitors Quipt Home Medical Competitors P3 Health Partners Competitors Exagen Competitors Burning Rock Biotech Competitors Marpai Competitors Concord Medical Services Competitors OpGen Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:ENZ) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enzo Biochem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enzo Biochem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENZ Stock Alerts